Steven M. Mennen
Steven M. Mennen has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Alan H. Cherney
Drug Substance Technologies, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
3 shared publications Jason S. Tedrow
Process Development , Amgen, Inc. , 360 Binney Street , Cambridge , Massachusetts 02142 , United States
2 shared publicationsMargaret M. Faul
Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
2 shared publications- Scott J. Miller
Yale University
2 shared publications - Seb Caille
Drug Substance Technologies - Synthetics, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
2 shared publications - Shawn D. Walker
Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
2 shared publications
Latest Publications
- 10 December 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 25 (3) , 648-653
Process Development and Protein Engineering Enhanced Nitroreductase-Catalyzed Reduction of 2-Methyl-5-nitro-pyridine
- 10 December 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 25 (3) , 648-653
Process Development and Protein Engineering Enhanced Nitroreductase-Catalyzed Reduction of 2-Methyl-5-nitro-pyridine
- 15 July 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (8) , 1558-1567
Development of a Factory Process for Omecamtiv Mecarbil, a Novel Cardiac Myosin Activator
- 15 July 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (8) , 1558-1567
Development of a Factory Process for Omecamtiv Mecarbil, a Novel Cardiac Myosin Activator
- Top Cited PapersOpen Access
- 7 May 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (6) , 1213-1242
The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future
High-throughput experimentation (HTE) has revolutionized the pharmaceutical industry, most notably allowing for rapid screening of compound libraries against therapeutic targets. The last decade has also witnessed the extension of HTE principles toward the realm of small-molecule process chemistry. Today, most major pharmaceutical companies have created dedicated HTE groups within their process development teams, invested in automation technology to accelerate screening, or both. The industry’s commitment to accelerating process development has led to rapid innovations in the HTE space. This review will deliver an overview of the latest best practices currently taking place within our teams in process chemistry by sharing frequently-studied transformations, our perspective for the next several years in the field, and manual and automated tools to enable experimentation. A series of case studies are presented to exemplify state-of-the-art workflows developed within our laboratories.
- 7 May 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (6) , 1213-1242
Top Cited PapersOpen AccessThe Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future
High-throughput experimentation (HTE) has revolutionized the pharmaceutical industry, most notably allowing for rapid screening of compound libraries against therapeutic targets. The last decade has also witnessed the extension of HTE principles toward the realm of small-molecule process chemistry. Today, most major pharmaceutical companies have created dedicated HTE groups within their process development teams, invested in automation technology to accelerate screening, or both. The industry’s commitment to accelerating process development has led to rapid innovations in the HTE space. This review will deliver an overview of the latest best practices currently taking place within our teams in process chemistry by sharing frequently-studied transformations, our perspective for the next several years in the field, and manual and automated tools to enable experimentation. A series of case studies are presented to exemplify state-of-the-art workflows developed within our laboratories.
- 27 March 2019
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 84 (8) , 4583-4603
Molecular Complexity as a Driver for Chemical Process Innovation in the Pharmaceutical Industry
A Perspective of our work in the development of innovative synthetic methods within the discipline of Process Research and Development is presented. Through an overview of some of the programs that we have worked on during the past decade, we have selected cases studies to illustrate the challenges faced in development of robust chemical processes for molecules on a multi-kilogram scale. The examples have been selected to demonstrate the innovative chemistry being developed within our laboratories with a focus on fragment design, asymmetric synthesis, new synthetic reagents, and the methods that have allowed us to deliver cost-effective syntheses under reduced timelines in an increasingly competitive environment. The technical challenges are presented in the context of molecule complexity that while increasing in the portfolio of small molecules being developed inspires us to deliver new solutions. Overall, our goal is to highlight the exciting work that can be done within our field to support the discovery and delivery of medicines to patients.
- 27 March 2019
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 84 (8) , 4583-4603
Molecular Complexity as a Driver for Chemical Process Innovation in the Pharmaceutical Industry
A Perspective of our work in the development of innovative synthetic methods within the discipline of Process Research and Development is presented. Through an overview of some of the programs that we have worked on during the past decade, we have selected cases studies to illustrate the challenges faced in development of robust chemical processes for molecules on a multi-kilogram scale. The examples have been selected to demonstrate the innovative chemistry being developed within our laboratories with a focus on fragment design, asymmetric synthesis, new synthetic reagents, and the methods that have allowed us to deliver cost-effective syntheses under reduced timelines in an increasingly competitive environment. The technical challenges are presented in the context of molecule complexity that while increasing in the portfolio of small molecules being developed inspires us to deliver new solutions. Overall, our goal is to highlight the exciting work that can be done within our field to support the discovery and delivery of medicines to patients.
- 16 November 2018
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 38 (1) , 97-102
Xantphos as a Branch-Selective Ligand for the Acyclic sec-Alkyl Negishi Cross-Coupling of Heteroaryl Halides
- 16 November 2018
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 38 (1) , 97-102
Xantphos as a Branch-Selective Ligand for the Acyclic sec-Alkyl Negishi Cross-Coupling of Heteroaryl Halides
- 27 March 2008
- Published by Wiley in ChemInform
- Vol. 39 (16)
ChemInform Abstract: Asymmetric Catalysis Mediated by Synthetic Peptides
ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
- 27 March 2008
- Published by Wiley in ChemInform
- Vol. 39 (16)
ChemInform Abstract: Asymmetric Catalysis Mediated by Synthetic Peptides
ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
- 9 May 2005
- Published by Wiley in ChemInform
- Vol. 36 (22)
A Peptide‐Catalyzed Asymmetric Stetter Reaction.
For Abstract see ChemInform Abstract in Full Text.
- 9 May 2005
- Published by Wiley in ChemInform
- Vol. 36 (22)
A Peptide‐Catalyzed Asymmetric Stetter Reaction.
For Abstract see ChemInform Abstract in Full Text.